Does HepPar-1 immunoexpression have a role in differential diagnosis of periampullary cancer?

Pathology

Volumn 40, Issue 1, 2008, Pages 35-41

  Gulluoglu, Mine G ^a   Karayigit, Ebru ^a   Ozden, Ilgin ^a   Kapran, Yersu ^a   Dizdaroglu, Ferhunde ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

CDX2; HepPar 1; Immunohistochemistry; MUC2; Periampullary cancer

Indexed keywords

HEPATOCYTE PARAFFIN 1; MONOCLONAL ANTIBODY; MUCIN 2; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DUCTAL ADENOCARCINOMA OF THE PANCREATIC HEAD; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PANCREATICODUODENECTOMY; PERIAMPULLARY ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY;

EID: 36448968529     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020701716391     Document Type: Article

References (51)

1. Kimura W, Ohtsubo K. Incidence, sites of origin, and immunohistochemical and histochemical characteristics of atypical epithelium and minute carcinoma of the papilla of Vater. Cancer 1988; 61: 1394-402.
2. Kimura W, Futakawa N, Yamagata S, et al. Different clinicopathologic findings in two different histologic subtypes of carcinoma of papilla of Vater. Jpn J Cancer Res 1994; 85: 161-6.
3. Matsubayashi H, Watanabe H, Yamaguchi T, et al. Differences in mucus and K-ras mutation in relation to phenotypes of tumor of papilla of Vater. Cancer 1999; 86: 596-607.
4. Albores-Saavedra J, Henson DE, Klimstra DS. Tumors of the Extrahepatic Bile Ducts, and Ampulla of Vater. Atlas of Tumor Pathology, Third Series, Fascicle 27. Washington, DC: Armed Forces Institute of Pathology, 2000; 272-80.
5. Kimura W, Futakawa N, Zhao B. Neoplastic diseases of the papilla of Vater. J Hepatobiliary Pancreat Surg 2004; 11: 223-31.
6. Drummond F., Putt W, Fox M. Clonning and chromosome assignment of the human CDX2 gene. Ann Hum Genet 1997; 61: 393-400.
7. Kim YS. Mucin glycoproteins in gastrointestinal malignancies and metastasis. Eur J Gastroenterol 1993; 5: 219-25.
8. James R, Erler T, Kazenwadel J. Structure of the murine homebox gene cdx-2: expression in embryonic and adult intestinal epithelium. J Biol Chem 1994; 269: 15229-37.
9. Silberg DG, Swain GP, Suh ER, Traber TG. CDx1 and CDx2 expression during intestinal development. Gastroenterology 2000; 119: 961-71.
10. Lynch JP, Silberg DG. To differentiate of proliferate? The interaction between PI13K/PTEN and Cdx2. Gastroenterology 2002; 123: 1395-7.
11. Suh E, Traber PG. An intestine-specific homebox gene regulates proliferation and differentiation. Mol Cell Biol 1996; 16: 619-25.
12. De Lott LB, Morrison C, Suster S, et al. CDX2 is a useful marker intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites. Arch Pathol Lab Med 2005; 129: 1100-5.
13. Fan Z, Li J, Dong B, Huang X. Expression of CDX2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis. Clin Cancer Res 2005; 11: 6162-70.
14. Werling RW, Haziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin. An immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003; 27: 303-10.
15. Matsumoto K, Mizoshita T, Tsukamoto T, et al. CDx2 expression in pancreatic tumors: Relationship with prognosis of invasive ductal carcinomas. Oncol Rep 2004; 12: 1239-43.
16. Mazziotta RM, Borczuk AC, Powel CA, Mansukhani M. CDX2 immunostaining as a gastrointestinal marker. Expression in lung carcinomas is a potential pitfall. Appl Immunohistochem Mol Morphol 2005; 13: 55-60.
17. Kaimaktchiev V, Terracciano L, Tornillo L, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol 2004; 17: 1392-9.
18. Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma. Am J Surg Pathol 2005; 29: 359-67.
19. Ortiz-Rey JA, Alvarez C, San Miguel P, et al. Expression of CDX2, cytokeratins 7 and 20 in sinonasal intestinal-type adenocarcinoma. Appl Immunohistochem Mol Morphol 2005; 13: 142-6.
20. Phillips RW, Frierson HF, Moskaluk CA. CDX2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003; 27: 1442-7.
21. Cathro HP, Mills SE. Immunophenotypic differences between intestinal-type and low-grade papillary sinonasal adenocarcinomas. An immunohistochemical study of 22 cases utilizing CDX2 and MUC2. Am J Surg Pathol 2004; 23: 1026-32.
22. Hong SM, Cho H, Moskaluk CA, et al. CDX2 and MUC2 protein expression in extrahepatic bile duct carcinoma. Am J Clin Pathol 2005; 124: 361-70.
23. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin expression in normal and neoplastic tissues. Cancer Res 1993; 53: 641-51.
24. Lee MJ, Lee HS, Kim WH, et al. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol 2003; 16: 403-10.
25. Zhou H, Schaefer N, Wolff M, Fischer HP. Carcinoma of the ampulla of Vater. Comparative and histologic/immunohistochemical classification and follow-up. Am J Surg Pathol 2004; 28: 875-82.
26. Yonezawa S, Nakamura A, Horinouchi M, Sato E. The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. J Hepatobiliary Pancreat Surg 2002; 9: 328-41.
27. Adsay NV, Merati K, Andea A, et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol 2002; 15: 1087-95.
28. Steininger H, Pfofe DA, Muller H, et al. Expression of CDX2 and MUC2 in Barrett's mucosa. Pathol Res Pract 2005; 201: 573-7.
29. Lord RV, Brabender J, Wickramasinghe K, et al. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Surgery 2005; 138: 924-31.
30. Wennerberg AE, Nalesnik MA, Coleman WB. Hepatocyte Paraffin 1: A monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am J Pathol 1993; 143: 1050-4.
31. Pang Y, von Turkovich M, Wu H, et al. The binding of thyroid transcription factor-1 and hepatocyte paraffin 1 to mitochondrial proteins in hepatocytes: a molecular and immunoelectron microscopy study. Am J Clin Pathol 2006; 125: 722-6.
32. Lamps LW, Folpe AL. The diagnostic value of Hepatocyte Paraffin 1 antibody in differentiating hepatocellular neoplasms from nonhepatic tumors: A review. Adv Anat Pathol 2003; 10: 39-43.
33. Lugli A, Tornillo L, Mirlacher M, et al. Hepatcyte Paraffin 1 expression in human normal and neoplastic tissues. Tissue microarray analysis on 3940 tissue samples. Am J Clin Pathol 2004; 122: 721-7.
34. Minervini MI, Demetris AJ, Lee RG, et al. Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol 1997; 10: 686-92.
35. Kumagai I, Masuda T, Sato S, Ishikawa K. Immunoreactivity to monoclonal antibody, Hep Par 1, in human hepatocellular carcinomas according to grade and histological pattern. Hepatol Res 2001; 20: 312-9.
36. Chu PG, Ishigawa S, Wu E, Weiss LM. Hepatocyte antigen as a marker of hepatocellular carcinoma: An immunohistochemical comparison to carcinoembrionic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol 2002; 26: 978-88.
37. Villari D, Caruso R, Grosso M, et al. Hep Par 1 in gastric and bowel carcinomas: an immunohistochemical study. Pathology 2002; 34: 423-6.
38. Kanitakis J, Chouvet B, Claudy A, Scoazec JY. Immunoreactivity of Hepatocyte Paraffin 1 monoclonal antibody in cutaneous metastatic tumors. Am J Clin Pathol 2004; 122: 85-9.
39. Thamboo TP, Wee A. Hep Par 1 expression in carcinoma of the cervix: implications for diagnosis and prognosis. J Clin Pathol 2004; 57: 48-53.
40. Fan Z, van de Rijn M, Montgomery K, Rouse RV. Hep Par 1 antibody stain for the differential diagnosis of hepatocelleular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol 2003; 16: 137-44.
41. Ramos-Vara JA, Miller MA. Immunohistochemical characterization of canine intestinal epithelial and masenchymal tumors with a monoclonal antibody to hepatocyte paraffin 1 (Hep Par 1). Histochem J 2002; 34: 397-401.
42. Lee HS, Kim WH, Kang GH. Hepatocyte expressions in hepatocellular carcinomas, gastrointestinal neoplasms, and non-neoplastic gastrointestinal mucosa: its role as a diagnostic marker. J Korean Med Sci 2003; 18: 842-8.
43. Chu PG, Jiang Z, Weiss LW. Hepatocyte antigen as a marker of intestinal metaplasia. Am J Surg Pathol 2003; 27: 952-9.
44. Joo M, Kim H, Kim MK, et al. Expression of Ep-CAM in intestinal metaplasia, gastric epithelial dysplasia and gastric adenocarcinoma. J Gastroenterol Hepatol 2005; 20: 1039-45.
45. Hansel DE, Maitra A, Lin JW, et al. Expression of the caudal-type homeodomain transcription factors CDX1/2 and outcome in carcinomas of the ampulla of Vater. J Clin Oncol 2005; 23: 1811-8.
46. Fasano M, Theise ND, Nalesnik M, et al. Immunohistochemical evaluation of hepatoblastomas with use of the hepatocyte-specific marker, hepatocyte paraffin 1, and the polyclonal carcinoembrionic antigen. Mod Pathol 1998; 11: 934-8.
47. Sugiki T, Yamamoto M, Aruga A, et al. Immunohistochemical evaluation of single small hepatocellular carcinoma with negative staining of monoclonal antibody Hepatocyte Paraffin 1. J Surg Oncol 2004; 88: 104-7.
48. Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol 2002; 33: 1175-81.
49. Morrison C, Marsh W Jr, Flankel WL. A comparison of CD10 to pCEA, MOC31, and hepatocyte for the distinction of malignant tumors in the liver. Mod Pathol 2002; 15: 1279-87.
50. Siddiqui MT, Saboorian MH, Gokaslan ST, et al. Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in the fine needle aspiration samples. Cancer 2002; 96: 49-52.
51. Kakar S, Muir T, Murphy LM, et al. Immunoreactivity of Hep Par 1 in hepatic and extrahapatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma. Am J Clin Pathol 2003; 119: 361-6.